Compare BHM & NEPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BHM | NEPH |
|---|---|---|
| Founded | 2022 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.4M | 40.1M |
| IPO Year | 2022 | 2004 |
| Metric | BHM | NEPH |
|---|---|---|
| Price | $8.36 | $3.64 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $15.00 | $6.00 |
| AVG Volume (30 Days) | ★ 7.5K | 6.6K |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | ★ 4.54% | N/A |
| EPS Growth | N/A | ★ 1000.00 |
| EPS | N/A | ★ 0.01 |
| Revenue | ★ $68,734,000.00 | $18,789,000.00 |
| Revenue This Year | N/A | $11.24 |
| Revenue Next Year | N/A | $11.58 |
| P/E Ratio | ★ N/A | $377.00 |
| Revenue Growth | ★ 36.88 | 32.67 |
| 52 Week Low | $8.05 | $2.66 |
| 52 Week High | $14.45 | $6.42 |
| Indicator | BHM | NEPH |
|---|---|---|
| Relative Strength Index (RSI) | 33.77 | 49.79 |
| Support Level | $8.05 | $3.19 |
| Resistance Level | $9.60 | $3.78 |
| Average True Range (ATR) | 0.28 | 0.24 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 0.00 | 44.74 |
Bluerock Homes Trust Inc owns and operates a portfolio of institutional residential properties including single-family homes, build-to-rent communities, and other residential communities located in attractive markets with a focus on the knowledge-economy and high-quality of life growth markets of the Sunbelt and Western United States. The company's principal objective is to generate attractive risk-adjusted returns on investments where it believes it can drive growth in funds from operations and net asset value by acquiring residential units, developing residential communities, and through value-add renovations. The company has two reportable segments, consisting of Residential Communities, which derives maximum revenue; and Scattered Single-family homes.
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of revenue from product sales and a small amount from royalty revenue and other revenues.